How to manage acute promyelocytic leukemia

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

(2011) Y. Shen et al.   BLOOD

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid

(2011) J. H. Park et al.   BLOOD

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment

(2011) E. Goto et al.   BLOOD

Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models

(2011) Raajit K. Rampal et al.   JOURNAL OF CLINICAL INVESTIGATION

Newly Diagnosed Acute Promyelocytic Leukemia: Arsenic Moves Front and Center

(2011) Elihu H. Estey   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia

(2011) Ardeshir Ghavamzadeh et al.   JOURNAL OF CLINICAL ONCOLOGY

Modern Approaches to Treating Acute Promyelocytic Leukemia

(2011) Miguel A. Sanz et al.   JOURNAL OF CLINICAL ONCOLOGY

Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry

(2011) S Lehmann et al.   LEUKEMIA

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

(2010) M. A. Sanz et al.   BLOOD

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

(2010) F. Lo-Coco et al.   BLOOD

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

(2010) B. L. Powell et al.   BLOOD

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

(2010) P. Montesinos et al.   BLOOD

PML/RARα Targets Promoter Regions Containing PU.1 Consensus and RARE Half Sites in Acute Promyelocytic Leukemia

(2010) Kankan Wang et al.   CANCER CELL

PML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3

(2010) Marion Jeanne et al.   CANCER CELL

Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data

(2010) Vikram Mathews et al.   JOURNAL OF CLINICAL ONCOLOGY

Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector

(2010) J. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Arsenic Trioxide Controls the Fate of the PML-RAR  Oncoprotein by Directly Binding PML

(2010) X. W. Zhang et al.   SCIENCE

Use of All-trans Retinoic Acid in Combination with Arsenic Trioxide for Remission Induction in Patients with Newly Diagnosed Acute Promyelocytic Leukemia and for Consolidation/Maintenance in CR Patients

(2009) Chong-Wen Dai et al.   ACTA HAEMATOLOGICA

Comparison of Clinical Outcomes of Patients with Relapsed Acute Promyelocytic Leukemia Induced with Arsenic Trioxide and Consolidated with Either an Autologous Stem Cell Transplant or an Arsenic Trioxide–Based Regimen

(2009) Rajasekar Thirugnanam et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

(2009) L. Ades et al.   BLOOD

Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia

(2009) J. Zhou et al.   BLOOD

How I treat acute promyelocytic leukemia

(2009) M. S. Tallman et al.   BLOOD

The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation

(2009) H. Boukarabila et al.   GENES & DEVELOPMENT

Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation

(2009) M. Breccia et al.   HAEMATOLOGICA

Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience

(2009) Charikleia Kelaidi et al.   JOURNAL OF CLINICAL ONCOLOGY

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG

(2009) E Lengfelder et al.   LEUKEMIA

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

(2009) J. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

(2008) J. de la Serna et al.   BLOOD

Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations

(2008) T. Akagi et al.   BLOOD

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

(2008) P. Montesinos et al.   BLOOD

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

(2008) M. A. Sanz et al.   BLOOD

Stem cell regulation by polycomb repressors: postponing commitment

(2008) Alexandra M Pietersen et al.   CURRENT OPINION IN CELL BIOLOGY

Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

(2008) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

PML targeting eradicates quiescent leukaemia-initiating cells

(2008) Keisuke Ito et al.   NATURE

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

(2008) Rihab Nasr et al.   NATURE MEDICINE

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma

(2007) E. Fox et al.   BLOOD